FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475833483> ?p ?o ?g. }

• W2475833483 abstract "Background: Nivo, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, is approved in the United States and European Union for the treatment of pts with advanced SQ NSCLC refractory to prior chemotherapy, based on results of phase 2 (CheckMate 063) and phase 3 (CheckMate 017) trials. In these studies, PD-1 ligand (PD-L1) expression was neither predictive nor prognostic of survival benefit. Here we present results of exploratory analyses from these studies evaluating the potential correlation of baseline serum cytokines with overall survival (OS) in pts with SQ NSCLC. Methods: Baseline serum cytokine concentrations in evaluable pts from CheckMate 063 and CheckMate 017 treated with nivo (n = 222) or doc (n = 118) were analyzed using a custom HumanMAP quantitative multiplexed immunoassay (Myriad RBM, Austin, TX). Multivariate analyses using a stepwise variable selection were performed in a Cox model using a 6:4 training:test validation in nivo-treated subjects. The performance of the association with OS of the identified cytokine set in nivo-treated subjects was tested using time-varying receiver-operating characteristic (ROC) analysis. SQ-cytoscore, generated to quantify the effect of the identified cytokine set on OS, was computed as follows: 1) calculation of the tertile bin distribution of each cytokine in the set in all pts and assignment of a point score (0, 1, or 2) for each tertile expression of each cytokine; 2) calculation of SQ-cytoscore for each pt as the sum of points; 3) categorization of pts as SQ-cytoscore “high” or “low” based on the median cutoff. OS was analyzed in pts with high vs low SQ-cytoscore treated with nivo and doc using the Kaplan-Meier method and 18-mo data cutoffs for CheckMate 063 (June 2015) and CheckMate 017 (August 2015). Results: Of 26 evaluable baseline cytokines, a set of 14 was identified to be associated with OS. Median OS was longer in pts with high vs low SQ-cytoscore in both nivo- and doc-treated cohorts (nivo [n = 102 vs 120]: 15.6 vs 5.3 months, HR:0.48, 95%CI:0.36-0.64, P Conclusion: In pts with advanced SQ NSCLC pooled from 2 clinical trials, a set of serum cytokines (details to be presented) potentially associated with OS benefit was identified. The benefit of a high SQ-cytoscore appeared more profound in pts treated with nivo vs doc. These preliminary findings require prospective validation in future studies. Citation Format: Benedetto Farsaci, William J. Geese, Kaushal D. Desai, Chelsea Jin, Scott J. Antonia, Herve Lena, Leora Horn, David Planchard, Karen L. Reckamp, Thomas E. Stinchcombe, Scott Gettinger, Hossein Borghaei, Matthew D. Hellmann, Christopher Harbison, Dong Xu, M. Anne Blackwood-Chirchir, Naiyer Rizvi. Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-072." @default.
• W2475833483 created "2016-08-23" @default.
• W2475833483 creator A5003220273 @default.
• W2475833483 creator A5012061864 @default.
• W2475833483 creator A5012282947 @default.
• W2475833483 creator A5014554706 @default.
• W2475833483 creator A5016915127 @default.
• W2475833483 creator A5028596081 @default.
• W2475833483 creator A5029805571 @default.
• W2475833483 creator A5040900859 @default.
• W2475833483 creator A5046273815 @default.
• W2475833483 creator A5051283101 @default.
• W2475833483 creator A5062894702 @default.
• W2475833483 creator A5070967174 @default.
• W2475833483 creator A5075781740 @default.
• W2475833483 creator A5075877134 @default.
• W2475833483 creator A5076652172 @default.
• W2475833483 creator A5077194786 @default.
• W2475833483 creator A5091701619 @default.
• W2475833483 date "2016-07-15" @default.
• W2475833483 modified "2023-09-25" @default.
• W2475833483 title "Abstract LB-072: Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017" @default.
• W2475833483 doi "https://doi.org/10.1158/1538-7445.am2016-lb-072" @default.
• W2475833483 hasPublicationYear "2016" @default.
• W2475833483 type Work @default.
• W2475833483 sameAs 2475833483 @default.
• W2475833483 citedByCount "0" @default.
• W2475833483 crossrefType "proceedings-article" @default.
• W2475833483 hasAuthorship W2475833483A5003220273 @default.
• W2475833483 hasAuthorship W2475833483A5012061864 @default.
• W2475833483 hasAuthorship W2475833483A5012282947 @default.
• W2475833483 hasAuthorship W2475833483A5014554706 @default.
• W2475833483 hasAuthorship W2475833483A5016915127 @default.
• W2475833483 hasAuthorship W2475833483A5028596081 @default.
• W2475833483 hasAuthorship W2475833483A5029805571 @default.
• W2475833483 hasAuthorship W2475833483A5040900859 @default.
• W2475833483 hasAuthorship W2475833483A5046273815 @default.
• W2475833483 hasAuthorship W2475833483A5051283101 @default.
• W2475833483 hasAuthorship W2475833483A5062894702 @default.
• W2475833483 hasAuthorship W2475833483A5070967174 @default.
• W2475833483 hasAuthorship W2475833483A5075781740 @default.
• W2475833483 hasAuthorship W2475833483A5075877134 @default.
• W2475833483 hasAuthorship W2475833483A5076652172 @default.
• W2475833483 hasAuthorship W2475833483A5077194786 @default.
• W2475833483 hasAuthorship W2475833483A5091701619 @default.
• W2475833483 hasConcept C121608353 @default.
• W2475833483 hasConcept C126322002 @default.
• W2475833483 hasConcept C143998085 @default.
• W2475833483 hasConcept C203092338 @default.
• W2475833483 hasConcept C2776256026 @default.
• W2475833483 hasConcept C2777701055 @default.
• W2475833483 hasConcept C2778690821 @default.
• W2475833483 hasConcept C2780030458 @default.
• W2475833483 hasConcept C2781190966 @default.
• W2475833483 hasConcept C535046627 @default.
• W2475833483 hasConcept C58471807 @default.
• W2475833483 hasConcept C71924100 @default.
• W2475833483 hasConceptScore W2475833483C121608353 @default.
• W2475833483 hasConceptScore W2475833483C126322002 @default.
• W2475833483 hasConceptScore W2475833483C143998085 @default.
• W2475833483 hasConceptScore W2475833483C203092338 @default.
• W2475833483 hasConceptScore W2475833483C2776256026 @default.
• W2475833483 hasConceptScore W2475833483C2777701055 @default.
• W2475833483 hasConceptScore W2475833483C2778690821 @default.
• W2475833483 hasConceptScore W2475833483C2780030458 @default.
• W2475833483 hasConceptScore W2475833483C2781190966 @default.
• W2475833483 hasConceptScore W2475833483C535046627 @default.
• W2475833483 hasConceptScore W2475833483C58471807 @default.
• W2475833483 hasConceptScore W2475833483C71924100 @default.
• W2475833483 hasLocation W24758334831 @default.
• W2475833483 hasOpenAccess W2475833483 @default.
• W2475833483 hasPrimaryLocation W24758334831 @default.
• W2475833483 hasRelatedWork W1606039500 @default.
• W2475833483 hasRelatedWork W2015093111 @default.
• W2475833483 hasRelatedWork W2337494164 @default.
• W2475833483 hasRelatedWork W2339680551 @default.
• W2475833483 hasRelatedWork W2405704202 @default.
• W2475833483 hasRelatedWork W2480568007 @default.
• W2475833483 hasRelatedWork W2591995733 @default.
• W2475833483 hasRelatedWork W2740834062 @default.
• W2475833483 hasRelatedWork W2740839196 @default.
• W2475833483 hasRelatedWork W2741245320 @default.
• W2475833483 hasRelatedWork W2745601792 @default.
• W2475833483 hasRelatedWork W2763012859 @default.
• W2475833483 hasRelatedWork W2810274113 @default.
• W2475833483 hasRelatedWork W2955901534 @default.
• W2475833483 hasRelatedWork W3083269007 @default.
• W2475833483 hasRelatedWork W3175357812 @default.
• W2475833483 hasRelatedWork W3179719243 @default.
• W2475833483 hasRelatedWork W3180437044 @default.
• W2475833483 hasRelatedWork W3211460958 @default.
• W2475833483 hasRelatedWork W2246441943 @default.
• W2475833483 isParatext "false" @default.
• W2475833483 isRetracted "false" @default.
• W2475833483 magId "2475833483" @default.
• W2475833483 workType "article" @default.